Using nanotechnology to target therapy for triple negative breast cancer
Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
This study is exploring new ways to treat triple negative breast cancer using tiny particles to deliver special molecules that can help stop cancer cells from growing, aiming to create better treatment options that work specifically for this type of cancer and have fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project ID | NIH-10814962 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for triple negative breast cancer (TNBC), a type of breast cancer that currently lacks effective targeted treatments. The approach involves using nanotechnology to deliver small interfering RNA (siRNA) that can selectively inhibit cancer cell growth by targeting specific genetic alterations associated with TNBC. By understanding the genetic vulnerabilities of TNBC cells, particularly those with deletions in the TP53 and POLR2A genes, the research aims to create more effective treatment options. Patients may benefit from this targeted therapy that could improve treatment outcomes and reduce side effects compared to traditional therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those whose tumors exhibit TP53 and POLR2A genetic alterations.
Not a fit: Patients with other types of breast cancer or those whose tumors do not have the specific genetic alterations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatment options for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in using targeted therapies for cancer treatment, but this specific approach utilizing nanotechnology for TNBC is relatively novel.
Where this research is happening
College Park, United States
- Univ of Maryland, College Park — College Park, United States (Active)
Researchers
- Principal investigator: He, Xiaoming — Univ of Maryland, College Park
- Study coordinator: He, Xiaoming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.